Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on its use in the real-world setting is limited. The aim of the current study is to evaluate the outcomes and safety profile of bevacizumab in mCRC in a real-world setting in Romania. Patients and Methods: This was an observational, retrospective, multicentric, cohort study conducted in Romania that included patients with mCRC treated with bevacizumab as part of routine clinical practice. Study endpoints were progression-free survival, overall survival, adverse events, and patterns of bevacizumab use. Results: A total of 554 patients were included in the study between January 2008 and December 2018. A total of 392 patients (71%) received bevacizumab in the first line and 162 patients (29%) in the second line. Bevacizumab was mostly combined with a capecitabine/oxaliplatin chemotherapy regimen (31.6%). The median PFS for patients treated with bevacizumab was 8.4 months (interquartile range [IQR], 4.7–15.1 months) in the first line and 6.6 months (IQR, 3.8–12.3 months) in the second line. The median OS was 17.7 months (IQR, 9.3–30.6 months) in the first line and 13.5 months (IQR, 6.7–25.2 months) in the second line. Primary tumor resection was associated with a longer PFS and OS. The safety profile of bevacizumab combined with chemotherapy was similar to other observational studies in mCRC. Conclusions: The safety profile of bevacizumab was generally as expected. Although the PFS was generally similar to that reported in other studies, the OS was shorter, probably due to the less frequent use of bevacizumab after disease progression and the baseline patient characteristics. Patients with mCRC treated with bevacizumab who underwent resection of the primary tumor had a higher OS compared to patients with an unresected primary tumor.

No abstract

We report the case of a 55-year-old-male with a large cell metastatic pancreatic neuroendocrine carcinoma treated for 14 months with lanreotide autogel having a stable disease (SD) and not responding to chemotherapy. The somatostatin analogues (SSA) were introduced after an episode of diarrhea and controlled the disease. Progression-free survival (PFS) as determined by Computerized Tomography (CT) scans was obtained for 14 months. After more than a year, the patient's health state deteriorated along with progressive disease. The capecitabine-temozolomide regimen was challenged, but after three cycles, a rapid clinical decline was noted. Conclusion. This unexpected event (diarrhea) in the course of the disease could represent the beginning of carcinoid syndrome. While the lanreotide autogel helped the episode of diarrhea pass, it also helped gain control over the disease itself.

timeframes. Similar expression method was applied to hippocampi obtained from children with MTLE and normal controls. Results The expression pattern for the miR-124, miR-134 and miR-9 nearly showed the same dynamics in the three stages of MTLE development to be upregulated in the acute and chronic stages and nearly equal to the control in the latent stage, they upregulated also in the children with MTLE. Conclusions The significant upregualtion for the brain specific miR-124, miR-134 and miR-9 in the seizures related stages and children suggested that both can be a potential targets for anticonvulsant drugs in the epileptic developing brains. Background and aims Prematurity and intrauterine growth restriction (IUGR) is associated with deviations of the developmental trajectory of the brain. We aimed to examine resting state networks (RSNs) in preterm infants with and without IUGR during natural sleep at 12 months. Methods We included 30 preterm infants (<34 weeks) without focal brain lesions (12 with IUGR and 18 appropriate for gestational age) and 20 born-term infants that were scanned at 12 months during natural sleep. Structural and functional MRI was acquired in a 3T scanner. To account for head movement we performed frame censoring of the data. RSNs were computed using the MELODIC module (FSL software). Dual regression analysis was used to query between-group differences in RSNs. PO-0850Results Overall, the degree of movement on functional data was small. In the group we identified nine RSNs encompassing bilaterally the primary visual cortex, auditory cortex, sensori-motor cortex, lateral parietal cortex, precuneus, frontal and a sub-cortical network. Preterm infants had a more prominent cerebellar network compared to term infants. The three groups showed a fragmentized default-mode network. No significant differences were found between groups.Conclusions The spatial patterns of the RSNs observed in preterm and term infants corresponded closely to those observed in adults. These findings may suggest that IUGR and prematurity does not interfere with the normal process of functional brain network development at 12 months of age. The fact that we could not find differences in RSNs does not rule out that alterations could occur later in development. Background and aims Children with cerebral palsy (CP) and their caregivers often report poor quality sleep. A proportion of sleep problems can be linked to physical care needs associated with CP; need for repositioning, pain and hygiene. Simple but effective changes can be made to care regimes that may reduce sleep disturbance. However, sleep issues and the subsequent sleep solutions are frequently overlooked. The aim of this pilot study is to identify why children with CP and their parents/caregivers are awake at night-time. Methods Parents of children with severe CP aged between 6 and 10 years were asked to complete a Time Use Diary (TUD) of their child's night from 6 pm until 9 am for two nights. Results Eight families returned the study documents, yielding a tot...

Background and aims Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder generally characterised by inattention, distractibility, impulsivity, hyperactivity. Medication does not cure ADHD, but it is used to control the symptoms. The goal of the study was to determine the impact of pharmacologic treatment on symptoms control in ADHD paediatric patients. Methods The efficacy of pharmacologic treatment was assessed in 82 children patients of 5–12 years old diagnosed with ADHD. 33 patients received treatment with atomoxetine, 26 patients underwent treatment with methylphenidate and 23 patients weren’t receiving pharmacological treatment (control group). The ADHD symptoms were screened with parent-rated Child Symptom Inventory-4 (CSI-4) scale at first visit to the doctor and three months after. Results CSI-4 scale scores were statistically analysed. Between-subjects analysis taking as factor the treatment group highlighted a statistical significant difference (p < 0.001) between the two time points (baseline and 3 months after) which corresponds to an improvement of the disease symptoms. Conclusions Pharmacologic treatment significantly reduced the ADHD symptoms in children on the basis of parent-rate CSI-4 scoring. Medication doesn’t cure, but it has positive impact in the management of ADHD syndrome.